MOBILE, Ala. (BUSINESS WIRE) -
Dec. 19, 2000-–ThermaFreeze(TM)
Inc. (OTC BB: THFZ) announced a
joint development project with a
second innovative company with which it plans a joint venture
company combining ThermaFreeze(TM) refrigerant in an
innovative new product set.
The new, patentable packaging system, based on existing and
proprietary technologies, will actively protect temperature
sensitive critical shipments such as routine clinical laboratory
specimens, blood and human organs during transits up to 2-days.
This new, re-usable system is designed to replace current 2.5"
thick coolers that require tooling charges in excess of $50,000 and
one-way unit costs in excess of $12.00. ThermaFreeze (TM)
refrigerant will replace less efficient gel packs or dry ice that is
considered a hazardous material by carriers. Initial tests have
been 100% successful. The proposed joint venture company will
market this new temperature sensitive pharmaceutical protection
system to all worldwide pharmaceutical, medical and biotech
companies, replacing more expensive and less efficient methods.
Forward-looking statements in this release are made pursuant to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risk and uncertainties,
including without limitation, continued acceptance of the
Company's products, increased levels of competition for the
Company, new products and technological changes, the Company's
dependence on third party suppliers, intellectual property rights,
and other risks detailed from time to time in the Company's
periodic reports filed with the Securities and Exchange
Commission. This release conforms with the Securities and
Exchange Commission Fair Disclosure Regulation, effective,
October 2000.
Contact: ThermaFreeze(TM) Inc. Joseph C. Murray, 334/666-2011
thermafreeze.com |
